A Phase I, Open-label Study to Evaluate the Relative Bioavailability of IDX184 and Food Effect in Healthy Male Subjects

Trial Profile

A Phase I, Open-label Study to Evaluate the Relative Bioavailability of IDX184 and Food Effect in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2015

At a glance

  • Drugs IDX 184 (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 19 Nov 2012 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 16 Aug 2012 The US FDA has placed a partial clinical hold on IDX 184, according to a Idenix Pharmaceuticals media release.
    • 27 Apr 2011 Dosing has been completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top